Completion is expected on 22 February. The acquisition includes 18 prescription products across a range of therapeutic areas, including:

* ImmuCyst, an immunotherapy for superficial bladder cancer.

* Gelclair, an oral gel for the management of oral mucositis caused by chemotherapy and radiotherapy.

*Procarbazine, a treatment of Hodgkin's Lymphoma as part of chemotherapy treatment.

* Aa liquid formulation of Vitamin E, the only one licensed in the UK.

Alliance is raising £7.5m through a conditional placing and Lloyds Banking Group is providing an additional £4m term loan and has increased the existing £5m working capital facility to £6m.

Story provided by Business Financial Newswire